150 related articles for article (PubMed ID: 17119487)
1. [The course of the drug, clinical research and commercialization. Constraints, obstacles, delays and costs].
Giri I; Rouillon F
Encephale; 2006 Oct; 32(5 Pt 3):S858-60. PubMed ID: 17119487
[No Abstract] [Full Text] [Related]
2. Cutting the cost of drug development?
Rawlins MD
Nat Rev Drug Discov; 2004 Apr; 3(4):360-4. PubMed ID: 15060531
[No Abstract] [Full Text] [Related]
3. Patients not patents: Drug research and development as a public enterprise.
Gøtzsche PC
Eur J Clin Invest; 2018 Feb; 48(2):. PubMed ID: 29243246
[No Abstract] [Full Text] [Related]
4. [The economics of therapeutic investigations (author's transl)].
Poisvert M
Anesth Analg (Paris); 1980; 37(9-10):619-20, 623-6. PubMed ID: 7469079
[No Abstract] [Full Text] [Related]
5. Regulation of clinical research sponsored by pharmaceutical companies: a proposal.
Sotelo J
PLoS Med; 2006 Jul; 3(7):e306. PubMed ID: 16805651
[TBL] [Abstract][Full Text] [Related]
6. Market watch: Top drugs and companies by sales in 2017.
Urquhart L
Nat Rev Drug Discov; 2018 Mar; 17(4):232. PubMed ID: 29588516
[No Abstract] [Full Text] [Related]
7. Research and development costs for drugs.
Riggs TL
Lancet; 2004 Jan; 363(9404):184. PubMed ID: 14738789
[No Abstract] [Full Text] [Related]
8. We Can use Market Forces to Moderate Drug Prices.
Miller HI
Mo Med; 2019; 116(6):451-453. PubMed ID: 31911716
[No Abstract] [Full Text] [Related]
9. [From molecule to medicine--drug development].
Bruhn C
Dtsch Med Wochenschr; 2010 Feb; 135(6):p5. PubMed ID: 20151355
[No Abstract] [Full Text] [Related]
10. Benchmarking biopharmaceutical process development and manufacturing cost contributions to R&D.
Farid SS; Baron M; Stamatis C; Nie W; Coffman J
MAbs; 2020; 12(1):1754999. PubMed ID: 32449439
[TBL] [Abstract][Full Text] [Related]
11. [The long path (s) of placing medicines on the market].
Duguet C
Med Sci (Paris); 2019 Mar; 35 Hors série n° 1():13-17. PubMed ID: 30943154
[No Abstract] [Full Text] [Related]
12. Research and development costs for new drugs by therapeutic category. A study of the US pharmaceutical industry.
DiMasi JA; Hansen RW; Grabowski HG; Lasagna L
Pharmacoeconomics; 1995 Feb; 7(2):152-69. PubMed ID: 10155302
[TBL] [Abstract][Full Text] [Related]
13. Market watch: upcoming market catalysts in Q3 2012.
Jeng R
Nat Rev Drug Discov; 2012 Jun; 11(7):508. PubMed ID: 22743969
[No Abstract] [Full Text] [Related]
14. The calculus of cures.
Kocher R; Roberts B
N Engl J Med; 2014 Apr; 370(16):1473-5. PubMed ID: 24571723
[No Abstract] [Full Text] [Related]
15. Medical ethics, research and the pharmaceutical industry.
Abud-Mendoza C
Reumatol Clin; 2012; 8(5):233-5. PubMed ID: 22608694
[No Abstract] [Full Text] [Related]
16. The $2.6 billion pill--methodologic and policy considerations.
Avorn J
N Engl J Med; 2015 May; 372(20):1877-9. PubMed ID: 25970049
[No Abstract] [Full Text] [Related]
17. Costing drug development.
Nat Rev Drug Discov; 2003 Apr; 2(4):247. PubMed ID: 12680358
[No Abstract] [Full Text] [Related]
18. Developing drugs for tuberculosis.
Farlow A
Science; 2007 Feb; 315(5815):1076-7; author reply 1076-7. PubMed ID: 17322043
[No Abstract] [Full Text] [Related]
19. America's other drug problem: how the drug industry distorts medicine and politics.
Relman AS; Angell M
New Repub; 2002 Dec; 227(25):27-41. PubMed ID: 12561803
[No Abstract] [Full Text] [Related]
20. The extinction of drugs for clinical research: Can the ECNP medicines chest save them?
Nutt D; Kilpatrick G; Hayes A
Eur Neuropsychopharmacol; 2014 Apr; 24(4):487-90. PubMed ID: 24508534
[No Abstract] [Full Text] [Related]
[Next] [New Search]
